Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [
]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's “home
country”), or under the
rules of the home country exchange on which the registrant's
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K shall be incorporated
by reference into the Company's effective Registration Statements
on Form F-3, as amended and supplemented (Registration Statement
Nos. 333-172796 and 333-218297), filed with the Securities and
Exchange Commission, from the date on which this Report is filed,
to the extent not superseded by documents or reports subsequently
filed or furnished by Intellipharmaceutics International Inc. under
the Securities Act of 1933 or the Securities Exchange Act of
1934.
As previously announced, on April 7, 2017, Intellipharmaceutics
International Inc. (the “Company”) received notice that
Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F.
Laboratories, Inc., Rhodes Technologies, and another party had
commenced patent infringement proceedings against the Company in
the U.S. District Court for the District of Delaware in respect of
the Company’s new drug application filing for Oxycodone ER. A
trial date was set for October 22, 2018.
On October 4, 2018, the parties to the case mutually agreed to
postpone the scheduled court date pending a case status conference
scheduled for December 17, 2018.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew Patient
|
|
Date:
October 5, 2018
|
Andrew
Patient
Chief Financial Officer
|